Tag: NASDAQ: CLSD

Business

Clearside Biomedical Inc (NASDAQ: CLSD) Proclaims Optimistic Security Consequences from Cohort 1 of OASIS Phase 1/2a Clinical Pilot of CLS-AX

Clearside Biomedical Inc (NASDAQ: CLSD), a biopharmaceutical company, proclaimed today optimistic security consequences from Cohort 1 of OASIS, its continuing Phase 1/2a scientific pilot of CLS-AX (axitinib injectable suspension) managed by suprachoroidal injection via Clearside’s SCS Microinjector® in six patients (n=6) with neovascular age-related macular degeneration (wet AMD). The main […]

Business

Clearside Biomedical Inc (NASDAQ: CLSD) Proclaims Constructive Security Consequences from Unit 1 of OASIS Phase 1/2a Medical Pilot of CLS-AX for the Treatment of Wet AMD

Clearside Biomedical Inc (NASDAQ: CLSD), a biopharmaceutical company devoted to evolving and transporting actions that reinstate and uphold a vision for persons with grave back of the eye illnesses, proclaimed today positive care results from Cohort 1 of OASIS, its continuing Phase 1/2a medical pilot of CLS-AX managed by suprachoroidal […]